HomeALIM • NASDAQ
Alimera Sciences Inc
$3.90
After Hours:
$3.90
(0.00%)0.00
Closed: Mar 28, 4:30:00 PM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed securityUS headquartered
Previous close
$3.90
Day range
$3.76 - $4.01
Year range
$1.56 - $4.38
Market cap
204.18M USD
Avg Volume
86.09K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
(USD)Dec 2023Y/Y change
Revenue
26.31M87.51%
Operating expense
21.96M56.69%
Net income
-3.78M-0.03%
Net profit margin
-14.3746.66%
Earnings per share
-0.0787.71%
EBITDA
3.76M364.14%
Effective tax rate
-0.19%
Total assets
Total liabilities
(USD)Dec 2023Y/Y change
Cash and short-term investments
12.06M128.63%
Total assets
153.52M260.37%
Total liabilities
107.35M69.30%
Total equity
46.17M
Shares outstanding
52.35M
Price to book
4.43
Return on assets
1.18%
Return on capital
1.58%
Net change in cash
(USD)Dec 2023Y/Y change
Net income
-3.78M-0.03%
Cash from operations
3.77M1,601.99%
Cash from investing
-85.00K-1.19%
Cash from financing
-78.00K59.59%
Net change in cash
3.77M1,685.71%
Free cash flow
5.45M1,286.46%
About
Alimera Sciences, Inc. is a biopharmaceutical sales company based in Alpharetta, Georgia that specializes in the commercialization and sales of prescription ophthalmic pharmaceuticals. The company's main selling focus is on diseases affecting the back of the eye, or retina. The company is the licensee for Iluvien, a fluocinolone acetonide intravitreal implant. Wikipedia
Founded
2003
Employees
157
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu